Research ArticleOMERACT 11
How to Choose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Approves Filter 2.0
Maarten Boers, John R. Kirwan, Laure Gossec, Philip G. Conaghan, Maria-Antonietta D’Agostino, Clifton O. Bingham III, Peter M. Brooks, Robert Landewé, Lyn March, Lee Simon, Jasvinder A. Singh, Vibeke Strand, George A. Wells and Peter Tugwell
The Journal of Rheumatology May 2014, 41 (5) 1025-1030; DOI: https://doi.org/10.3899/jrheum.131314
Maarten Boers
From the Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam,
The Netherlands; University of Bristol, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol,
UK; Université Pierre et Marie Curie (UPMC) — Paris 6, GRC-UMPC 08 (EEMOIS), Paris,
France; APHP, Hôpital Pitié-Salpêtrière, Rhumatologie; University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds,
UK; Department of Rheumatology, APHP, Ambroise Paré Hospital, UPRES EA 2506 Université Versailles-Saint Quentin En Yvelines, Boulogne-Billancourt,
France; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland,
USA; Australian Health Workforce Institute, School of Population Health, University of Melbourne, Melbourne,
Australia; Academic Medical Center University of Amsterdam and Atrium Medical Center Heerlen, Heerlen,
The Netherlands; Institute of Bone and Joint Research and Sydney Medical School and School of Public Health, University of Sydney, and Department of Rheumatology, Royal North Shore, St. Leonards, NSW,
Australia; SDG LLC, Cambridge, Massachusetts; University of Alabama at Birmingham; Veterans Affairs Medical Center, Birmingham, Alabama; Mayo Clinic College of Medicine, Rochester, Minnesota; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California,
USA; Department of Epidemiology and Community Medicine, and Department of Medicine, University of Ottawa, Ottawa, Ontario,
Canada.
John R. Kirwan
Laure Gossec
Philip G. Conaghan
Maria-Antonietta D’Agostino
Clifton O. Bingham III
Peter M. Brooks
Robert Landewé
Lyn March
Lee Simon
Jasvinder A. Singh
Vibeke Strand
George A. Wells

REFERENCES
- 1.↵
- 2.↵
- 3.↵
- Wells G,
- Anderson J,
- Beaton D,
- Bellamy N,
- Boers M,
- Bombardier C,
- et al.
- 4.↵
- Kirwan JR
- 5.↵
- Kirwan J,
- Heiberg T,
- Hewlett S,
- Hughes R,
- Kvien T,
- Ahlmen M,
- et al.
- 6.↵
- Kirwan JR,
- Minnock P,
- Adebajo A,
- Bresnihan B,
- Choy E,
- de Wit M,
- et al.
- 7.↵
- Boers M,
- Tugwell P,
- Felson DT,
- van Riel PLCM,
- Kirwan JR,
- Edmonds JP,
- et al.
- 8.↵
- Tugwell PS,
- Petersson IF,
- Boers M,
- Gossec L,
- Kirwan JR,
- Rader T,
- et al.
- 9.↵
- Idzerda L,
- Rader T,
- Tugwell P,
- Boers M
- 10.↵International Classification of Diseases (ICD-10). World Health Organization, 1990. [Internet. Accessed January 17, 2014.] Available from: www.who.int/classifications/icd/en
- 11.↵
- International Classification of Functioning Disability and Health (ICF)
- 12.↵Patient-Reported Outcomes Measurement Information System (PROMIS), 2012. [Internet. Accessed January 17, 2014.] Available from: www.nihpromis.org
- 13.↵
- 14.↵
- Boers M,
- Idzerda L,
- Kirwan JR,
- Beaton D,
- Escorpizo R,
- Boonen A,
- et al.
- 15.↵
- Kirwan JR,
- Fries JF,
- Hewlett SE,
- Osborne RH,
- Newman S,
- Ciciriello S,
- et al.
- 16.↵
- Kirwan JR,
- Boers M,
- Hewlett S,
- Beaton D,
- Bingham CO,
- Choy E,
- et al.
- 17.↵
- Tugwell P,
- Boers M,
- D’Agostino M,
- Beaton D,
- Boonen A,
- Bingham CO,
- et al.
- 18.↵
- Wells GA,
- Beaton D,
- Tugwell P,
- Boers M,
- Kirwan JR,
- Bingham CO III.,
- et al.
- 19.↵
- 20.↵
- Kirwan JR,
- Bartlett SJ,
- Beaton D,
- Boers M,
- Bosworth A,
- Brooks PM,
- et al.
- 21.↵Guidance for industry — patient-reported outcome measures: Use in medical product development to support labeling claims. United States Department of Health and Human Services, Food and Drug Administration (FDA), 2009. [Internet. Accessed January 17, 2014.] Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf
- 22.↵
- 23.↵
- Sanderson TC,
- Hewlett SE,
- Flurey C,
- Dures E,
- Richards P,
- Kirwan JR
- 24.↵
- D’Agostino MA,
- Boers M,
- Dougados M,
- Van Der Heijde D,
- Iagnocco A,
- Landewe RBM,
- et al.
- 25.↵
- Bernard HR
- 26.↵
- Boers M,
- Kirwan JR,
- Wells G,
- Beaton D,
- Gosseo L,
- D’Agostino M,
- et al.
In this issue
The Journal of Rheumatology
Vol. 41, Issue 5
1 May 2014
How to Choose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Approves Filter 2.0
Maarten Boers, John R. Kirwan, Laure Gossec, Philip G. Conaghan, Maria-Antonietta D’Agostino, Clifton O. Bingham, Peter M. Brooks, Robert Landewé, Lyn March, Lee Simon, Jasvinder A. Singh, Vibeke Strand, George A. Wells, Peter Tugwell
The Journal of Rheumatology May 2014, 41 (5) 1025-1030; DOI: 10.3899/jrheum.131314
How to Choose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Approves Filter 2.0
Maarten Boers, John R. Kirwan, Laure Gossec, Philip G. Conaghan, Maria-Antonietta D’Agostino, Clifton O. Bingham, Peter M. Brooks, Robert Landewé, Lyn March, Lee Simon, Jasvinder A. Singh, Vibeke Strand, George A. Wells, Peter Tugwell
The Journal of Rheumatology May 2014, 41 (5) 1025-1030; DOI: 10.3899/jrheum.131314